Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
1. 10 crore teleconsultations have been rendered to senior citizens and 5,22,15,224 to women
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Subscribe To Our Newsletter & Stay Updated
